BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 212917)

  • 1. ACTH and cortisol response to bromocriptine, and results of long-term therapy, in Cushing's disease.
    Kennedy AL; Sheridan B; Montgomery DA
    Acta Endocrinol (Copenh); 1978 Nov; 89(3):461-8. PubMed ID: 212917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy.
    Whitehead HM; Beacom R; Sheridan B; Atkinson AB
    Clin Endocrinol (Oxf); 1990 Feb; 32(2):193-201. PubMed ID: 2161298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.
    Verhelst JA; Trainer PJ; Howlett TA; Perry L; Rees LH; Grossman AB; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):169-78. PubMed ID: 1657460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of bromocriptine in pituitary-dependent Cushing's syndrome.
    Boscaro M; Benato M; Mantero F
    Clin Endocrinol (Oxf); 1983 Oct; 19(4):485-91. PubMed ID: 6313262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine.
    Atkinson AB; Kennedy AL; Sheridan B
    Postgrad Med J; 1985 Mar; 61(713):239-42. PubMed ID: 2984649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cushing's disease: clinical and laboratory response to bromocriptine therapy.
    de Pinho MO; Antunes RC; Lima MB; Francalanci CC; Franco S
    J Endocrinol Invest; 1984 Dec; 7(6):585-8. PubMed ID: 6099377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of bromocriptine on ACTH levels in patients with bilateral adrenalectomy for pituitary-dependent Cushing's syndrome.
    O'Mullane N; Walker B; Jefferson J; Hipkin L; Diver M; Davis C
    J Endocrinol Invest; 1978 Oct; 1(4):355-7. PubMed ID: 229153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic Cushing's disease in long-term remission with a daily low dose of bromocriptine.
    Adachi M; Takayanagi R; Yanase T; Sakai Y; Ikuyama S; Nakagaki H; Osamura Y; Sanno N; Nawata H
    Intern Med; 1996 Mar; 35(3):207-11. PubMed ID: 8785455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of Cushing's disease successfully treated with bromocriptine.
    Sumiya N; Hiramatsu K; Arimori S
    Jpn J Med; 1990; 29(2):185-90. PubMed ID: 2172607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term bromocriptine therapy in Cushing's disease.
    Kapcala LP; Jackson IM
    J Endocrinol Invest; 1982; 5(2):117-20. PubMed ID: 6284830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cortisol-suppressible dexamethasone-nonsuppressible cyclic Cushing's disease with evidence of clinical and biochemical remission with bromocriptine.
    Mercado-Asis LB; Murayama M; Yamakita N; Morita H; Mune T; Yasuda K; Miura K
    Endocrinol Jpn; 1991 Jun; 38(3):315-24. PubMed ID: 1665413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease.
    Mercado-Asis LB; Yasuda K; Murayama M; Mune T; Morita H; Miura K
    Endocrinol Jpn; 1992 Aug; 39(4):385-95. PubMed ID: 1332855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of injectable bromocriptine in patients with Cushing's disease.
    Invitti C; De Martin M; Danesi L; Cavagnini F
    Exp Clin Endocrinol Diabetes; 1995; 103(4):266-71. PubMed ID: 7584534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Unique type of Cushing's disease in clinical profile: cyclic Cushing's syndrome and Cushing's disease with favorable outcome to a high daily dose of bromocriptine].
    Yasuda K; Miura K
    Nihon Naibunpi Gakkai Zasshi; 1994 Jan; 70(1):11-6. PubMed ID: 7958078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug controlled of Cushing's syndrome. Combined aminoglutethimide and metyrapone therapy.
    Child DF; Burke CW; Burley DM; Rees LH; Fraser TR
    Acta Endocrinol (Copenh); 1976 Jun; 82(2):330-41. PubMed ID: 179256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease.
    Dickstein G; DeBold CR; Gaitan D; DeCherney GS; Jackson RV; Sheldon WR; Nicholson WE; Orth DN
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2934-41. PubMed ID: 8768855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of pituitary tumor size with clinical and biochemical improvement with bromocriptine in a normoprolactinemic Cushing's disease.
    Hayashi H; Mercado-Asis LB; Murayama M; Yamakita N; Yasuda K; Miura K
    Endocrinol Jpn; 1990 Dec; 37(6):875-82. PubMed ID: 1966282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adrenostatic treatment of ACTH-dependent Cushing syndrome using metyrapone and aminoglutethimide].
    Reincke M; Allolio B; Jaursch-Hancke C; Kaulen D; Winkelmann W
    Dtsch Med Wochenschr; 1987 Oct; 112(40):1532-5. PubMed ID: 2820688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACTH-independent Cushing's syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone.
    Close CF; Mann MC; Watts JF; Taylor KG
    Clin Endocrinol (Oxf); 1993 Sep; 39(3):375-9. PubMed ID: 8222300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of metyrapone pretreatment on adrenocorticotropin secretion induced by corticotropin-releasing hormone in normal subjects and patients with Cushing's disease.
    Totani Y; Niinomi M; Takatsuki K; Oiso Y; Tomita A
    J Clin Endocrinol Metab; 1990 Mar; 70(3):798-803. PubMed ID: 2155255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.